SECONDARY ANALYSIS OF CRISP PILOT STUDY DATA

这项研究的目的是进行二次分析 老年人降低胆固醇计划(CRISP)数据集。至少一个 手稿将写在以下每个主题上。 1.坚持的预测：我们假设POR坚持将是 与受教育程度低、年龄较大、男性、黑人种族、没有 心血管疾病和大量同时服药。 依从性将通过药片计数、临床就诊次数和低密度脂蛋白来衡量 各治疗组均有变化(安慰剂组除外)。 2.安慰剂磨合的效用：我们假设依从性较差的人 安慰剂的磨合预示着治疗阶段的依从性较差。穷 依从性(药片数量低于75%)和良好依从者(药片数量 超过75%)在试运行阶段将与坚持进行比较 测量后随机化。 3.治疗对生活质量的影响：假设 洛伐他汀(两种剂量)对生活质量几乎没有影响。 将通过比较两个活跃的治疗组和 安慰剂组对多项生活质量进行测量。 4.对饮食的脂质反应：记录血脂变化(如有) 采用贝叶斯方法对饮食进行调整，回归到均值。 认为饮食变化与年龄、种族、性别无关的无效假设 性别和教育程度将进行测试。 5.CRISP参与者与CHS参与者的比较：WE 假设受制于血脂标准，清脆的参与者将 展示出比CHS参与者更健康的个人资料。他们将被比较 关于基线特征，包括年龄、种族、BP、 受教育程度、吸烟、不同性别的血脂水平、心血管疾病 还有服药。

The purpose of the study is to conduct secondary analyses of The Cholesterol Reduction in Seniors Program (CRISP) data set. At least one manuscript will be written on each of the following topics. 1. Prediction of Adherence: We hypothesize that por adherence will be associated with low education, greater age, male gender, black race, no cardiovascular disease and large number of concurrent medications. Adherence will be measured by pill count, clinic attendance and LDL-C change (except placebo group) in each treatment group. 2. Utility of a Placebo Run-in: We hypothesize that poor adherence at placebo run-in will predict poor adherence in the treatment phase. Poor adherence (pill count less than 75%) and good adherers (pill count greater than 75%) at the run-in phase will be compared to adherence measures post-randomization. 3. Effect of Treatment on Quality of Life: The hypothesis that lovastatin (at either dose) will have little effect on quality of life will be tested by comparing the two active treatment groups and the placebo group over a number of quality of life measures. 4. Lipid Response to Diet: Documentation of serum lipid change (if any) to diet will be adjusted for regression to the mean using Bayes method. The null hypothesis that diet change is not associated with age, race, gender and educational attainment will be tested. 5. Comparison of CRISP Participants with CHS Participants: We hypothesize that subject to the lipid criteria, CRISP participants will exhibit a healthier profile than CHS participants. They will be compared with respect to baseline characteristics including age, race, BP, education, smoking, gender specific lipid levels, cardiovascular disease and medication taking.